|Bid||124.13 x 1000|
|Ask||125.07 x 800|
|Day's range||124.09 - 125.54|
|52-week range||87.68 - 132.30|
|Beta (5Y monthly)||0.80|
|PE ratio (TTM)||47.00|
|Earnings date||24 Aug 2021|
|Forward dividend & yield||2.52 (2.01%)|
|Ex-dividend date||24 Jun 2021|
|1y target est||140.12|
Vanta utilizes Medtronic's (MDT) proprietary AdaptiveStim technology for personalized pain relief.
STROKE AF trial shows Medtronic's (MDT) Reveal LINQ ICM has a seven-fold advantage in detecting AF compared to traditional standard of care in patients with large vessel or small vessel stroke.
Medtronic's (MDT) SenSight claims to deliver patient-specific DBS therapy for the treatment of symptoms associated with Parkinson's, dystonia and essential tremor and medically refractory epilepsy.